Physician profile
Malcolm Symes
NPI 1477040277
$1,058.45
in general payments reported to CMS, 2019-2025
14 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $178 · 2023: $318 · 2024: $319 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $243.30 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $172.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $170.81 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $114.68 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $78.16 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.02 | 2022-2025 | Xifaxan |
| Astellas Pharma US INC | $45.88 | 2024 | Veozah |
| Amgen INC. | $41.10 | 2022-2023 | Prolia, Evenity |
| Abbvie INC. | $29.17 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $24.14 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $22.07 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.22 | 2024 | Rexulti |
| Cranial Technologies, INC | $17.43 | 2023 | Doc Band |
| Viatris Specialty LLC | $15.71 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Symes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.